RespireRx Pharmaceuticals (RSPI) Stock Price, News & Analysis

Company Overview

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Key Stats

• Today's Range: $0.0023 to $0.0023
• 50-Day Range: N/A
• 52-Week Range: $0.0002 to $0.0069
• Volume: N/A
• Average Volume: 467,028 shs
• Market Capitalization: $2.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSPI Stock Analysis - Frequently Asked Questions

How have RSPI shares performed this year?

RespireRx Pharmaceuticals' stock was trading at $0.0008 at the beginning of the year. Since then, RSPI stock has increased by 187.5% and is now trading at $0.0023.
View the best growth stocks for 2025 here.

How were RespireRx Pharmaceuticals' earnings last quarter?

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) released its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RespireRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RespireRx Pharmaceuticals investors own include American Bio Medica (ABMC), Galaxy Next Generation (GAXY), Asia Broadband (AABB), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET) and AMC Entertainment (AMC).

Company Calendar

• Last Earnings: 8/19/2020
• Today: 4/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RSPI
• CIK: 849636
• Web: www.respirerx.com
• Phone: (201) 444-4947
• Fax: 949-727-3657
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 949,464,000
• Free Float: 474,447,000
• Market Cap: $2.18 million
• Optionable: Not Optionable
• Beta: 0.74